Jovana Lekovich1, Alexandre L S Lobel2, Joshua D Stewart3, Nigel Pereira2, Isaac Kligman2, Zev Rosenwaks2. 1. The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, 1305 York Avenue, 6th floor, New York, NY, 10021, USA. jol9105@med.cornell.edu. 2. The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, 1305 York Avenue, 6th floor, New York, NY, 10021, USA. 3. Department of Obstetrics and Gynecology, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA.
Abstract
PURPOSE: The purpose of this study is to investigate if female patients with lymphoma demonstrate diminished ovarian reserve prior to initiation of the lymphoma treatment. METHODS: Sixty-four patients with newly diagnosed lymphoma undergoing controlled ovarian hyperstimulation for fertility preservation were compared with 365 healthy controls undergoing elective oocyte cryopreservation (controlled ovarian hyperstimulation (COH)) and 128 patients with other types of malignancy prompting fertility preservation. The data of all lymphoma patients, all elective, and all the patients with other types of malignancy who met the inclusion criteria and underwent COH for fertility preservation during the study period were retrospectively analyzed. Primary outcomes included serum anti-Müllerian hormone (AMH) levels (ng/mL) and antral follicle count (AFC). RESULTS: Patients in the lymphoma group demonstrated significantly lower AMH levels and AFC and had less oocytes harvested and cryopreserved when compared to healthy controls as well as patients with other malignancies. CONCLUSION: Patients with lymphoma demonstrate diminished ovarian reserve when compared with healthy controls and patients with other malignancies. This should be taken into consideration when deciding on the dose for COH.
PURPOSE: The purpose of this study is to investigate if female patients with lymphoma demonstrate diminished ovarian reserve prior to initiation of the lymphoma treatment. METHODS: Sixty-four patients with newly diagnosed lymphoma undergoing controlled ovarian hyperstimulation for fertility preservation were compared with 365 healthy controls undergoing elective oocyte cryopreservation (controlled ovarian hyperstimulation (COH)) and 128 patients with other types of malignancy prompting fertility preservation. The data of all lymphomapatients, all elective, and all the patients with other types of malignancy who met the inclusion criteria and underwent COH for fertility preservation during the study period were retrospectively analyzed. Primary outcomes included serum anti-Müllerian hormone (AMH) levels (ng/mL) and antral follicle count (AFC). RESULTS:Patients in the lymphoma group demonstrated significantly lower AMH levels and AFC and had less oocytes harvested and cryopreserved when compared to healthy controls as well as patients with other malignancies. CONCLUSION:Patients with lymphoma demonstrate diminished ovarian reserve when compared with healthy controls and patients with other malignancies. This should be taken into consideration when deciding on the dose for COH.
Authors: Lauren N C Johnson; Katherine E Dillon; Mary D Sammel; Brenda L Efymow; Monica A Mainigi; Anuja Dokras; Clarisa R Gracia Journal: Reprod Biomed Online Date: 2013-01-19 Impact factor: 3.828
Authors: S Lie Fong; J A Visser; C K Welt; Y B de Rijke; M J C Eijkemans; F J Broekmans; E M Roes; W H M Peters; A C S Hokken-Koelega; B C J M Fauser; A P N Themmen; F H de Jong; I Schipper; J S E Laven Journal: J Clin Endocrinol Metab Date: 2012-09-19 Impact factor: 5.958
Authors: J G Bentzen; J L Forman; A Pinborg; Ø Lidegaard; E C Larsen; L Friis-Hansen; T H Johannsen; A Nyboe Andersen Journal: Reprod Biomed Online Date: 2012-09-16 Impact factor: 3.828
Authors: Miguel A Checa; Mario Brassesco; Margalida Sastre; Manuel Gómez; Julio Herrero; Laura Marque; Arturo Brassesco; Juan José Espinós Journal: Int J Womens Health Date: 2015-02-12
Authors: Richard A Anderson; Rachel Remedios; Amy A Kirkwood; Pip Patrick; Linsey Stevens; Laura Clifton-Hadley; Tom Roberts; Chris Hatton; Nagesh Kalakonda; Don W Milligan; Pam McKay; Clare Rowntree; Fiona M Scott; Peter W M Johnson Journal: Lancet Oncol Date: 2018-09-13 Impact factor: 54.433